Recently, immune checkpoint inhibitor (ICI) therapy, including cytotoxic T-lymphocyte antigen 4, programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) inhibitors, has revolutionized the treatment of several cancers.4 5 Pembrolizumab, a PD-1 inhibitor, has been approved as second-line treatment for patients with advanced PD-L1-positive cervical cancer. This evidence concerns the gene CD274 and cancer.